CA2412776A1 - Compositions controlling release ph range and/or speed - Google Patents
Compositions controlling release ph range and/or speed Download PDFInfo
- Publication number
- CA2412776A1 CA2412776A1 CA002412776A CA2412776A CA2412776A1 CA 2412776 A1 CA2412776 A1 CA 2412776A1 CA 002412776 A CA002412776 A CA 002412776A CA 2412776 A CA2412776 A CA 2412776A CA 2412776 A1 CA2412776 A1 CA 2412776A1
- Authority
- CA
- Canada
- Prior art keywords
- release
- range
- polymer
- release rate
- composition controlling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Abstract
Compositions controlling release pH range and/or speed which contain (i) theinotriazolodiazepine compounds represented by the following general formu la (I), (ii) at least one base selected from among water-soluble polymers, enteric polymers, water-insoluble polymers and porous polymers; and/or a surfactant; and a process for producing the same.
Claims (16)
1. A composition controlling a pH range of release and/or a release rate, which comprises (i) a thienotriazolodiazepine compound of the formula (I) wherein X is a halogen, R1 is C1-C4 alkyl, R1 is C1-C4 alkyl, a is an integer of 1-4, R3 is C1-C4 alkyl, C1-C4 hydroxyalkyl, C1-C4 alkoxy, phenyl optionally having substituent(s), or heteroaryl optionally having substituent(s), a pharmaceutically acceptable salt thereof or a hydrate thereof; and (ii) at least one kind of ingredient selected from the group consisting of a water-soluble polymer, an enteric polymer, a water-insoluble polymer and a porous polymer.
2. The composition controlling a pH range of release and/or a release rate of claim 1, which further comprises a surfactant.
3. A composition controlling a pH range of release and/or a release rate, which comprises the compound of the formula (I), a pharmaceutically acceptable salt thereof or a hydrate thereof, and a surfactant.
4. The composition controlling a pH range of release and/or a release rate of any of claims 1 to 3, wherein the compound of the formula (I) is (S)-2-[4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide.
5. The composition controlling a pH range of release and/or a release rate of any of claims 1 to 4, which is a therapeutic agent for an inflammatory disease in the neutral area in the gastrointestinal tract lumen.
6. The composition controlling a pH range of release and/or a release rate of claim 5, wherein the inflammatory disease is ulcerative colitis or Crohn's disease.
7. A production method of a composition controlling a pH range of release and/or a release rate, which comprises dissolving or dispersing the compound of the formula (I), a pharmaceutically acceptable salt thereof or a hydrate thereof, and a polymer in a solvent, and evaporating the solvent.
8. The method of claim 7, wherein the polymer is at least one kind selected from the group consisting of a water-soluble polymer, an enteric polymer, a water-insoluble polymer and a porous polymer.
9. The method of claim 7 or 8, further comprising dissolving or dispersing a surfactant in the solvent.
10. A production method of a composition controlling a pH range of release and/or a release rate, which comprises dissolving or dispersing the compound of the formula (I), a pharmaceutically acceptable salt thereof or a hydrate thereof, and a surfactant in a solvent, and evaporating the solvent.
11. A composition controlling a pH range of release and/or a release rate, which is obtainable by the method of any of claims 7 to 10.
12. A production method of a composition controlling a pH range of release and/or a release rate, which comprises melting the compound of the formula (I), a pharmaceutically acceptable salt thereof or a hydrate thereof, dissolving or dispersing a polymer, and cooling for solidification.
13. The method of claim 12, wherein the polymer is at least one kind selected from the group consisting of a water-soluble polymer, an enteric polymer, a water-insoluble polymer and a porous polymer.
14. The method of claim 12 or 13, further comprising dissolving or dispersing a surfactant in the melt product.
15. A production method of a composition controlling a pH range of release and/or a release rate, which comprises melting the compound of the formula (I), a pharmaceutically acceptable salt thereof or a hydrate thereof, dissolving or dispersing a surfactant, and cooling for solidification.
16. A composition controlling a pH range of release and/or a release rate which is obtainable by the method of any of claims 12 to 15.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000182293 | 2000-06-16 | ||
JP2000-182293 | 2000-06-16 | ||
PCT/JP2001/005151 WO2001095912A1 (en) | 2000-06-16 | 2001-06-15 | COMPOSITIONS CONTROLLING RELEASE pH RANGE AND/OR SPEED |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2412776A1 true CA2412776A1 (en) | 2001-12-20 |
CA2412776C CA2412776C (en) | 2011-03-15 |
Family
ID=18683084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2412776A Expired - Lifetime CA2412776C (en) | 2000-06-16 | 2001-06-15 | Compositions controlling release ph range and/or speed |
Country Status (7)
Country | Link |
---|---|
US (4) | US20030130268A1 (en) |
EP (1) | EP1297836A4 (en) |
JP (1) | JP4875277B2 (en) |
KR (1) | KR100838686B1 (en) |
AU (1) | AU2001264303A1 (en) |
CA (1) | CA2412776C (en) |
WO (1) | WO2001095912A1 (en) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006056781A (en) * | 2002-11-15 | 2006-03-02 | Bioserentack Co Ltd | Solidified preparation containing surfactant |
JP2004339162A (en) * | 2003-05-16 | 2004-12-02 | Shin Etsu Chem Co Ltd | Pharmaceutical solid preparation containing sparingly soluble medicine and method for producing the same |
JP2007308480A (en) * | 2006-04-20 | 2007-11-29 | Shin Etsu Chem Co Ltd | Solid preparation containing enteric solid dispersion |
JP5576922B2 (en) * | 2006-04-20 | 2014-08-20 | 信越化学工業株式会社 | Solid formulation comprising an enteric solid dispersion |
JP2010189337A (en) * | 2009-02-19 | 2010-09-02 | Asahi Breweries Ltd | Granule and tablet containing poorly soluble substance, and method for solubilizing poorly soluble substance |
US20100319928A1 (en) * | 2009-06-22 | 2010-12-23 | Baker Hughes Incorporated | Through tubing intelligent completion and method |
US20110000674A1 (en) * | 2009-07-02 | 2011-01-06 | Baker Hughes Incorporated | Remotely controllable manifold |
US20110073323A1 (en) * | 2009-09-29 | 2011-03-31 | Baker Hughes Incorporated | Line retention arrangement and method |
WO2011143657A1 (en) | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc. | Male contraceptive compositions and methods of use |
PL2902030T3 (en) | 2010-05-14 | 2017-07-31 | Dana-Farber Cancer Institute, Inc. | Thienotriazolodiazepine compounds for treating neoplasia |
JP5935030B2 (en) | 2010-05-14 | 2016-06-15 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | Compositions and methods for treating leukemia |
AR084070A1 (en) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | BROMODOMINIUM INHIBITORS AND USES OF THE SAME |
WO2012075456A1 (en) | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals | Bromodomain inhibitors and uses thereof |
EP2705039B1 (en) | 2011-05-04 | 2017-07-26 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
EP2721031B1 (en) | 2011-06-17 | 2016-01-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
TWI602820B (en) | 2012-06-06 | 2017-10-21 | 星宿藥物公司 | Bromodomain inhibitors and uses thereof |
US9624244B2 (en) | 2012-06-06 | 2017-04-18 | Constellation Pharmaceuticals, Inc. | Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof |
RU2015115634A (en) * | 2012-09-28 | 2016-11-20 | Онкоэтикс Гмбх | PHARMACEUTICAL COMPOSITION containing thienotriazolodiazepine compounds |
BR112016001457A2 (en) | 2013-07-25 | 2017-08-29 | Dana Farber Cancer Inst Inc | TRANSCRIPTION FACTOR INHIBITORS AND THEIR USES |
JP6453877B2 (en) * | 2013-08-01 | 2019-01-16 | オンコエシックス ゲーエムベーハー | Pharmaceutical formulations containing thienotriazolodiazepine compounds |
WO2015018520A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma |
WO2015018523A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | A novel bet-brd inhibitor for treatment of solid tumors |
WO2015018522A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
US20160158246A1 (en) * | 2013-08-06 | 2016-06-09 | Oncoethix Gmbh | Method of treating diffuse large b-cell lymphoma (dlbcl) using a bet-bromodomain inhibitor |
CA2929652A1 (en) | 2013-11-08 | 2015-05-14 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors |
US9757385B2 (en) | 2013-11-27 | 2017-09-12 | Merck Sharp & Dohme Corp. | Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds |
WO2015078931A1 (en) * | 2013-11-27 | 2015-06-04 | Oncoethix Sa | Method of treating neuroblastomas using thienotriazolodiazepine compounds |
WO2015078928A1 (en) * | 2013-11-27 | 2015-06-04 | Oncoethix Sa | Method of treating non-small-cell lung cancer using pharmaceutical formulation containing thienotriazolodiazepine compounds |
WO2015117087A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
JP2017504653A (en) | 2014-01-31 | 2017-02-09 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
US10925881B2 (en) | 2014-02-28 | 2021-02-23 | Tensha Therapeutics, Inc. | Treatment of conditions associated with hyperinsulinaemia |
CA2947601A1 (en) | 2014-05-02 | 2015-11-05 | Oncoethix Gmbh | Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds |
KR20170002550A (en) * | 2014-05-02 | 2017-01-06 | 온코에틱스 게엠베하 | Method of treating resistant non-hodgkin lymphoma, medulloblastoma, and/or alk+ non-small cell lung cancer using thienotriazolodiazepine compounds |
WO2015169953A1 (en) | 2014-05-08 | 2015-11-12 | Oncoethix Gmbh | Method of treating glioma using thienotriazolodiazepine compounds |
JP2017519727A (en) | 2014-05-08 | 2017-07-20 | オンコエシックス ゲーエムベーハー | Method for treating three types of negative breast cancer using thienotriazolodiazepine compounds |
WO2015189814A1 (en) * | 2014-06-13 | 2015-12-17 | Oncoethix Gmbh | Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds |
RS58730B1 (en) | 2014-06-20 | 2019-06-28 | Constellation Pharmaceuticals Inc | Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide |
WO2016022970A1 (en) | 2014-08-08 | 2016-02-11 | Dana-Farber Cancer Institute, Inc. | Dihydropteridinone derivatives and uses thereof |
MX2017001756A (en) | 2014-08-08 | 2017-05-30 | Dana Farber Cancer Inst Inc | Diazepane derivatives and uses thereof. |
JP2017528446A (en) * | 2014-08-19 | 2017-09-28 | オンコエシックス ゲーエムベーハー | Method for treating lymphoma using thienotriazolodiazepine compound |
EP3185871A1 (en) * | 2014-08-28 | 2017-07-05 | Oncoethix GmbH | Methods of treating acute myeloid leukemia or acute lymphoid leukemia using pharmaceutical compositions containing thienotriazolodiazepine compounds |
EP3212654B1 (en) | 2014-10-27 | 2020-04-08 | Tensha Therapeutics, Inc. | Bromodomain inhibitors |
WO2016176335A1 (en) | 2015-04-27 | 2016-11-03 | Concert Pharmaceuticals, Inc. | Deuterated otx-015 |
CA2986441A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
WO2017044792A1 (en) | 2015-09-11 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Acetamide thienotriazoldiazepines and uses thereof |
AU2016319116B2 (en) | 2015-09-11 | 2020-10-01 | Dana-Farber Cancer Institute, Inc. | Cyano thienotriazolodiazepines and uses thereof |
BR112018009798A8 (en) | 2015-11-25 | 2019-02-26 | Dana Farber Cancer Inst Inc | bivalent bromodomain inhibitors and their uses |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56110612A (en) * | 1980-02-08 | 1981-09-01 | Yamanouchi Pharmaceut Co Ltd | Readily disintegrable and absorbable compression molded article of slightly soluble drug |
US5264446A (en) | 1980-09-09 | 1993-11-23 | Bayer Aktiengesellschaft | Solid medicament formulations containing nifedipine, and processes for their preparation |
FR2525108B1 (en) | 1982-04-19 | 1989-05-12 | Elan Corp Ltd | HIGH-SOLUBILITY MEDICINES AND PROCESS FOR OBTAINING THEM |
JPS5914446A (en) | 1982-07-13 | 1984-01-25 | Michio Yoshikawa | Overload detecting device |
IE63321B1 (en) * | 1986-02-03 | 1995-04-05 | Elan Corp Plc | Drug delivery system |
JP2773959B2 (en) * | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | Colon release solid preparation |
EP0661284A1 (en) * | 1992-09-18 | 1995-07-05 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienodiazepine compound and medicinal use thereof |
US5686105A (en) * | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
US5773025A (en) * | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
JPH07223970A (en) * | 1994-02-10 | 1995-08-22 | Tanabe Seiyaku Co Ltd | Releasing formulation at niche in digestive tract |
JPH07324086A (en) * | 1994-05-31 | 1995-12-12 | Sankyo Co Ltd | Solid dispersion of thiazolidine derivative or pharmaceutical preparation of solid dispersion |
JPH08143476A (en) * | 1994-11-18 | 1996-06-04 | Japan Tobacco Inc | Medicinal agent release-controlling membrane and solid preparation |
SG80553A1 (en) * | 1995-07-20 | 2001-05-22 | Tanabe Seiyaku Co | Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract |
EA001732B1 (en) * | 1996-09-13 | 2001-08-27 | Велфайд Корпорейшн | Thienotriazolodiazepine compounds and medicaments therefrom |
-
2001
- 2001-06-15 WO PCT/JP2001/005151 patent/WO2001095912A1/en active Application Filing
- 2001-06-15 CA CA2412776A patent/CA2412776C/en not_active Expired - Lifetime
- 2001-06-15 KR KR1020027017110A patent/KR100838686B1/en active IP Right Grant
- 2001-06-15 AU AU2001264303A patent/AU2001264303A1/en not_active Abandoned
- 2001-06-15 JP JP2002510090A patent/JP4875277B2/en not_active Expired - Fee Related
- 2001-06-15 EP EP01938708A patent/EP1297836A4/en not_active Withdrawn
-
2002
- 2002-12-16 US US10/319,568 patent/US20030130268A1/en not_active Abandoned
-
2008
- 2008-08-05 US US12/222,213 patent/US20090012064A1/en not_active Abandoned
-
2012
- 2012-04-17 US US13/448,538 patent/US8883777B2/en not_active Expired - Fee Related
-
2014
- 2014-10-24 US US14/522,983 patent/US20150045352A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2001095912A1 (en) | 2001-12-20 |
US20090012064A1 (en) | 2009-01-08 |
AU2001264303A1 (en) | 2001-12-24 |
US20150045352A1 (en) | 2015-02-12 |
EP1297836A4 (en) | 2007-06-13 |
US20120202798A1 (en) | 2012-08-09 |
KR100838686B1 (en) | 2008-06-16 |
JP4875277B2 (en) | 2012-02-15 |
EP1297836A1 (en) | 2003-04-02 |
CA2412776C (en) | 2011-03-15 |
US8883777B2 (en) | 2014-11-11 |
KR20030010724A (en) | 2003-02-05 |
US20030130268A1 (en) | 2003-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2412776A1 (en) | Compositions controlling release ph range and/or speed | |
JP2002541259A5 (en) | ||
CA2331873A1 (en) | Fumagillol derivatives and processes for preparing the same | |
NO2015020I1 (en) | Ceritinib, 5-chloro-N-5-methyl-4- (piperidin-4-yl) -2 - [(propan-2-yl) oxy] phenyl-N- [2- (propan-2-sulfonyl) phenyl] pyrimidine-2,4-diamine, or a pharmaceutically acceptable salt thereof | |
CA2462211A1 (en) | Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors | |
JP2002529532A5 (en) | ||
KR970007493A (en) | Photo-crosslinkable liquid crystal 1,2-phenylene derivative | |
JP2003506525A5 (en) | ||
EP1618111B1 (en) | Salts of clopidogrel and process for preparation | |
CA2332087A1 (en) | Aryl substituted azabenzimidazoles and their use in the treatment of hiv and aids related diseases | |
CN101107000A (en) | 3,6-bicyclolides | |
JP2512759B2 (en) | Aqueous herbicidal compositions of imidazolinone herbicides | |
CN105777464A (en) | Hydroxamic acid derivative, and preparation method and application thereof | |
CA2423007A1 (en) | Spiro derivatives and adhesion molecule inhibitors containing the same as effective ingredients | |
JPH0558814A (en) | Anti-microbial composition and its preparation | |
CA2526991A1 (en) | Piperidinium and pyrrolidinium derivatives as ligands for the muscarinic m3 receptor | |
US4758427A (en) | Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone | |
JP2007529471A5 (en) | ||
RU2001123124A (en) | Chemical compounds | |
CA2393568A1 (en) | Diarylmethylpiperazines | |
CA2338498A1 (en) | Process for the synthesis of (1h)-benzo[c]quinolizin-3-ones derivatives | |
JPH03193799A (en) | 3-(l-pyrogultamil)-l-thiazolidine-4- carboxylic acid and preparation of its derivative | |
JP2006503056A5 (en) | ||
CN113891704A (en) | Caspase inhibitor prodrug injection composition | |
JP2003503517A (en) | A new purification method for aldehyde impurities |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20210615 |